Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"In-depth" 510(k) reviews will be completed within 90 days, CDRH's Burlington says.

This article was originally published in The Gray Sheet

Executive Summary

"IN-DEPTH REVIEW" ON ALL 510(K) SUBMISSIONS WITHIN 90 DAYS will be pursued by FDA's Center for Devices and Radiological Health for fiscal year 1996 (begun Oct. 1), CDRH Director Bruce Burlington says in a letter highlighting improvements in the center's device review program. "Our goal is to screen for completeness and perform at least one cycle of in-depth review on all submissions within a 90-day review cycle," Burlington says, at which time sponsors can expect to receive a determination of substantially equivalent, not substantially equivalent, or a request for additional data.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004951

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel